Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
The company's forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain's second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year. Top-selling Crestor, for high cholesterol, faces competition from cheap copycat drugs in 2016. The patent expiries leave AstraZeneca's sales on a near-term downward spiral at a time when most of its rivals have put their biggest patent losses behind them. Shares in the group rose 1.6 percent by 1215 GMT on the more upbeat outlook, against a 0.3 percent decline for the European healthcare sector. Chief Executive Pascal Soriot, who has been leading the company for a little more than a year, will set out the new revenue guidance in a presentation at the J.P. Morgan Healthcare conference in San Francisco later on Tuesday. The company will then give a more detailed update on its progress in full-year results on February 6. The consensus of analyst forecasts compiled by Thomson Reuters is for 2017 revenue of $22.5 billion, down from the $25.8 billion estimated for 2013. However, a number of the 2017 forecasts pre-date the diabetes drug deal struck last month that is already expected to add some $1 billion to $2 billion to annual revenue. Citigroup analyst Andrew Baum said the positive medium-term outlook reinforced his "more constructive thesis" for the stock, adding that he expects Soriot to strike more earnings-boosting deals this year. Panmure Gordon's Savvas Neophytou remains more wary, pointing out that Soriot's predecessor, David Brennan, had made a similar attempt to talk up AstraZeneca's longer-term prospects. "In our view, management is stepping onto thin ice with this same sort of guidance," Neophytou said, pointing out the previous management's failure to hit its forecasts. AstraZeneca has become more confident about its revenue outlook after the $4 billion deal last month to buy Bristol-Myers Squibb's share of a diabetes joint venture. The acquisition is expected to complete in the first quarter of 2014 and will boost sales immediately. Mark Clark of Deutsche Bank said this was set to lift analysts' revenue forecasts significantly, suggesting that a more realistic "adjusted consensus" for 2017 was around $24.3 billion rather than $22.5 billion. Soriot has been striking a number of bolt-on deals to refill the company's thin pipeline of new medicines and accelerating in-house research programs. The group now has 11 new-drug programs in late-stage Phase III testing, almost double the number a year ago, and 27 in Phase II. Hopes are particularly high for its cancer research, where it has started trials for immunotherapy combination treatments for which the first results are anticipated in 2014/15. AstraZeneca is behind the likes of Bristol-Myers, Roche and Merck & Co in the race to develop immunotherapies - a hot new area of cancer research - but it is betting on combination treatments to help it to catch up. Immunotherapy, which harnesses the body's immune system to fight cancer, has shown great promise in clinical trials and analysts believe that the treatments may extend patients' lives significantly and generate tens of billions of dollars in annual sales.

Ex Output:
Drugmaker AstraZeneca forecasts faster return to growth.

Ex Input:
File photo shows a young carer holding the hands of an elderly woman in a residential home for the elderly in Planegg near Munich June 19, 2007. REUTERS/Michaela Rehle The study, reported on Sunday in the journal BioMed Central BMC Neurology, involved 12 patients who had greatly improved language recall shortly after treatment with Enbrel, or etanercept, an anti-inflammatory drug co-marketed by Amgen and Wyeth. "We often see verbal effects within a few minutes of the first dose," said Dr. Edward Tobinick, director of the Institute for Neurological Research, a private medical group inc., in Los Angeles, who led the study. Tobinick invented and holds several patents on a special method of injecting the drug into the neck. He said he charges anywhere between $10,000 and $40,000 per patient for the treatments. In January, Tobinick's report on a single patient, and release of a striking video, drew the attention of the Alzheimer's Association, which released a statement expressing concern. "People with Alzheimer's and their families may place undue value on this new finding based on the dramatic language used in its description and the apparent immediate effect," the group said. "We need to see work in other laboratories by scientists without financial interest in the product," it added. Dr. Sam Gandy, chairman of the Alzheimer's Association's medical and science council, said the latest study, done at Tobinick's clinic, does not offer that independent confirmation. "It's still not a proper trial," Gandy said. Tobinick believes the drug may work in the brain by blocking an excess of tumor necrosis factor-alpha or TNF-alpha, which may affect communication in the brain. The study looked at language difficulties, such as in finding words, in 12 patients with mild-to-severe Alzheimer's disease who were administered etanercept weekly for six months. "There was a significant improvement in the majority of the verbal measures that were studied. The remainder showed a tendency toward improvement, which was not significant," Tobinick said in a telephone interview. He said the study provides evidence that "excess TNF, in the Alzheimer brain, may offer a new way to address this language dysfunction." Tobinick acknowledged the study is limited because people knew they were getting the drug. Alzheimer's patients in such open-label studies often show improvement. "Placebo effect is an enormous problem in open-label studies," said Dr. Scott Turner, incoming director of the Memory Disorders Program at Georgetown University Medical Center in Washington. Turner said the true test must come from a more scientifically rigorous double-blind, placebo-controlled, randomized clinical trial. In such studies, patients receive either a dummy treatment or an active agent, and neither the doctor nor the patient knows which. Amgen has also expressed concern about the research, claiming there has been insufficient evidence so far. "This off-label, unapproved treatment, administered by Dr. Edward Tobinick, is not supported nor endorsed by Amgen," the company said in April on its Web site. A video showing one woman's response to the drug in a sister study can be found at : here

Ex Output:
Drug restores speech in Alzheimer's; experts worry.

Ex Input:
"When President Trump announced a plan to suspend immigration to the United States, New York Sen. Kirsten Gillibrand tweeted the news with her own assessment of the decision: ""Immigrants make up a majority of essential workers in places like New York City,"" the Democrat wrote April 21. ""They're on the front lines of the battle against this pandemic. I stand with our immigrant communities now and always."" With so much dependent on the group of people that have become known as ""essential workers,"" we wanted to look closer at Gillibrand's statement to see if the numbers support it. Immigrants make up a majority of essential workers in places like New York Citythey're on the front lines of the battle against this pandemic. I stand with our immigrant communities now and always. https://t.co/3KvPLoztko We found that while the statistics on this question are a little murky, one credible study does reinforce her assertion. Gillibrand's communication's director, Evan Lukaske, told PolitiFact that the senator was defining essential worker based on the way the New York City comptroller's office defined ""frontline workers"" in its March 26 report, ""New York City's Frontline Workers."" The comptroller's report defined New York City's COVID-19 ""frontline workers"" as grocery, convenience, and drug store workers; public transit workers; trucking, warehouse, and U.S. Postal Service workers; health care workers; child care, homeless, food, and family services workers; and cleaning service workers. On March 20, New York Gov. Andrew Cuomo, a Democrat, and the New York State Department of Economic Development issued a guidance on the term ""essential worker,"" and it listed several categories of worker who would not be covered under the categories used in the comptroller's report, including those working at airports, certain types of manufacturing enterprises, hardware stores, funeral homes, animal shelters, and banks. Notably, the comptroller report's ""frontline worker"" category includes only ""direct-service, mostly non-governmental employees,"" meaning that it doesn't count most types of public employees. As a result, the report does not take into account police officers, firefighters, and other first responders. So while Lukaske said that Gillibrand ""is using 'frontline' and 'essential' as synonymous, there is a discrepancy between the two terms, and an alternate definition could end up changing the demographic profile. That said, the comptroller's report provides one reasonable definition. So what does the report's analysis show? According to the comptroller's study, more than 53% of frontline workers are foreign-born, meaning they're immigrants. Of the sectors studied, building cleaning services employs the highest share of immigrants at 70%. It is followed by health care and food and drug store workers, both at 53%. Other studies have backed up the broader proposition that immigrants make up a significant portion of essential workers. The Center for Migration Studies of New York, a think tank on international migration, has estimated that 1.8 million immigrants in New York state work in jobs the state considers ""essential businesses."" The think tank found that foreign-born workers make up 31.5% of workers in essential businesses in New York state, despite only representing 28% of the state's overall labor force. (It is logical that New York City's percentage would be higher, since immigrants represent a higher share of the population in the city than in the rest of the state.) Nationally, immigrants make up a ""sizable"" share of essential workers in the fight against the pandemic, said Michelle Mittelstadt, director of communications for the Migration Policy Institute. The group estimates that 6 million immigrants are working frontline jobs in health care, food production, and transportation, and another 6 million immigrants work in industries such as food services and domestic household services. ""You can assume that an immigrant-rich area like New York City might have higher shares of immigrants than the U.S. average in particular occupations,"" she said. Meanwhile, U.S. Census Bureau data shows that immigrants represent about 45% of the total workforce in New York City. That's in line with Gillibrand's assertion, said Jeffrey Passel, a senior demographer with the Pew Research Center. Gillibrand said that ""immigrants make up a majority of essential workers in places like New York City."" This number is backed up by a New York City comptroller's office study that found that 53% of all ""frontline"" workers in the city are immigrants. However, the comptroller office's definition, which doesn't include government workers such as first responders and which differs from the state's definition of ""essential workers,"" is only one way of analyzing the data, and other methods might produce a lower percentage."

Ex Output:
"Immigrants make up a majority of essential workers in places like New York City."